Therapeutic Area
Infectious Disease CDMOs
Compare CDMOs with infectious disease manufacturing expertise for antibiotics, antivirals, vaccines, and pandemic-readiness programs. Filter by biosafety level, modality, and capacity.
267 companies listed
About Infectious Disease Drug Manufacturing
Infectious disease manufacturing covers antibiotics (small molecule, complex natural products), antivirals (small molecule and biologic), vaccines (live-attenuated, inactivated, subunit, mRNA), and emerging modalities like monoclonal antibodies for prophylaxis. Post-pandemic, governments and organizations are investing heavily in manufacturing surge capacity and platform technologies.
Biosafety containment is essential for vaccine production. Live-attenuated vaccines require BSL-2 manufacturing. Viral challenge studies and certain vector production require BSL-3. CDMOs must demonstrate validated biosafety engineering controls, decontamination procedures, and personnel training. Ask about their biosafety committee oversight and facility classification.
Speed-to-scale capability differentiates infectious disease CDMOs. Pandemic preparedness programs prioritize CDMOs that can scale from clinical to commercial manufacturing within months, not years. Platform technologies (mRNA manufacturing lines, modular single-use bioreactors) enable rapid campaign switching between products. The ability to handle multiple products in segregated suites is a key differentiator.
Companies (267)
7bridges (the7bridges.com)
United Kingdom
7bridges (the7bridges.com) is a pharmaceutical CDMO offering comprehensive services.
Small Molecule APISmall Molecule Drug ProductOral Solid Dose
Avara Pharmaceutical Services
United States
Avara Pharmaceutical Services is a pharmaceutical CDMO offering comprehensive services.
Small Molecule APISmall Molecule Drug ProductOral Solid Dose
Frequently Asked Questions
What biosafety levels are needed for vaccine manufacturing?+
It depends on the vaccine type. Inactivated and subunit vaccines can often be manufactured at BSL-1 after the pathogen inactivation step. Live-attenuated vaccines require BSL-2 containment during production. Manufacturing involving live pathogenic organisms (challenge strains, certain vector production) may require BSL-3. mRNA vaccines do not require high biosafety levels since no live pathogen is involved -- a significant manufacturing advantage.
How has pandemic preparedness changed CDMO requirements?+
Post-COVID, the industry expects CDMOs to offer: platform manufacturing capabilities (especially mRNA and viral vector platforms), surge capacity planning with documented scale-up timelines, flexible facility designs that allow rapid campaign changeover, and warm-base manufacturing agreements where facilities maintain readiness for rapid activation. Government agencies (BARDA, CEPI, HERA) now include manufacturing readiness in their funding criteria.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
